Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
Dev Cell. 2019 Feb 11;48(3):329-344.e5. doi: 10.1016/j.devcel.2018.11.035. Epub 2018 Dec 27.
Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report that SPOP suppresses stem cell traits of both embryonic stem cells and PrCa cells through promoting Nanog poly-ubiquitination and subsequent degradation. Mechanistically, Nanog, but not other pluripotency-determining factors including Oct4, Sox2, and Klf4, specifically interacts with SPOP via a conservative degron motif. Importantly, cancer-derived mutations in SPOP or at the Nanog-degron (S68Y) disrupt SPOP-mediated destruction of Nanog, leading to elevated cancer stem cell traits and PrCa progression. Notably, we identify the Pin1 oncoprotein as an upstream Nanog regulator that impairs its recognition by SPOP and thereby stabilizes Nanog. Thus, Pin1 inhibitors promote SPOP-mediated destruction of Nanog, which provides the molecular insight and rationale to use Pin1 inhibitor(s) for targeted therapies of PrCa patients with wild-type SPOP.
SPOP 频繁突变定义了人类前列腺癌(PrCa)七种亚型之一的分子特征。然而,SPOP 如何作为前列腺癌中的肿瘤抑制因子发挥作用在很大程度上仍不清楚。在这里,我们报告 SPOP 通过促进 Nanog 的多泛素化和随后的降解来抑制胚胎干细胞和前列腺癌细胞的干细胞特性。在机制上,Nanog 而非其他多能性决定因子(包括 Oct4、Sox2 和 Klf4)通过保守的降解基序特异性地与 SPOP 相互作用。重要的是,SPOP 或 Nanog 降解基序(S68Y)中的癌症衍生突变会破坏 SPOP 介导的 Nanog 降解,导致癌症干细胞特性升高和前列腺癌进展。值得注意的是,我们确定 Pin1 癌蛋白是 Nanog 的上游调节因子,它会损害其被 SPOP 的识别,从而稳定 Nanog。因此,Pin1 抑制剂促进 SPOP 介导的 Nanog 降解,这为使用 Pin1 抑制剂(针对野生型 SPOP 的前列腺癌患者的靶向治疗)提供了分子见解和依据。